New Drug may Help Infants With Genetic Disorder Gain Motor Function

New Drug may Help Infants With Genetic Disorder Gain Motor Function

by Rishika Gupta on  February 16, 2018 at 6:09 PM Health Watch
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights
  • Nusinersen, a new drug may help infants with spinal muscular atrophy (SMA) regain vital motor function.
  • SMA Type 1 occur in infants with disease specific genetic mutation and usually results in progressive muscle weakness.
  • Nusinersen showed that infants gain in motor function and also survive without any additional support.
The new drug Nusinersen may have a positive impact on the lives of infants with a severe form of spinal muscular atrophy (SMA) finds a new study. Babies with this debilitating and deadly disease are usually destined to have a short lifespan and limited motor function. The findings of this study are published in the New England Journal of Medicine.
New Drug may Help Infants With Genetic Disorder Gain Motor Function

"This treatment is transformative for the entire SMA community," said Richard S. Finkel, M.D., the chief of neurology at Nemours Children's Hospital in Orlando and the senior author of the study. "One thing we have learned, though, is that the closer to symptom onset that children begin treatment, the more substantial the improvement in motor function. However, even with delayed use, we observed significant improvements in older children with SMA on nusinersen."

SMA is classified based on the age at symptom onset, as well as the most advanced motor milestone attained during development. Past studies have evaluated the safety of nusinersen in SMA Type 1, the most severe form that affects infants, usually before six months of age and who do not achieve sitting.

Children with SMA Type 2 experience symptoms after six months of age and attain sitting before experiencing the muscle weakness and decline in motor function that are hallmarks of this genetic disease.

Before nusinersen, no targeted drug treatments were available for SMA. This treatment modifies the SMN2 gene with an antisense oligonucleotide (ASO), a tiny fragment of synthetic DNA, injected directly into the spinal fluid. The DNA gets absorbed into nerve cells of the spinal cord to increase production of a protein required for neuromotor development.

The researchers noted greater improvements in a motor function score in children treated with nusinersen for at least six months. In total, 57 percent of children in the nusinersen group had an increase of at least three points in functioning scores from the start of the trial to the end of the examination period, compared with 26 percent of patients in the control group that achieved the same level improvement.

The study, known as the CHERISH trial, enrolled 126 children ages 2 to 12 with SMA Type 2 in a multicenter, randomized, double-blind, sham-controlled study from November 2014 through February 2017 to determine the safety and efficacy of the drug in these older patients. Children were administered four doses over nine months, followed by a six-month examination period, before being invited to participated in an open-label extension study.

There are some limitations to the study, including the strict eligibility criteria, which enrolled a more homogeneous and younger group of patients than those in clinical practice. Participants were required to be able to sit independently at the start of the study, with no severe contractures or scoliosis, limited ventilation support, and no use of a gastric feeding tube.

The availability of an effective treatment has led Dr. Finkel and colleagues to spearhead efforts to have SMA included in the Health Resources and Services Administration's Recommended Uniform Screening Panel, a newborn screening panel of conditions that warrant immediate identification after birth. The panel has recently approved this recommendation and is awaiting signature by the head of Health and Human Services. If included, infants with SMA could be diagnosed routinely and treated before symptoms appear.

Reference
  1. Richard S. Finkel, Eugenio Mercuri, Basil T. Darras, Anne M. Connolly, Nancy L. Kuntz, Janbernd Kirschner, Claudia A. Chiriboga, Kayoko Saito, Laurent Servais, Eduardo Tizzano, Haluk Topaloglu, Már Tulinius, Jacqueline Montes, Allan M. Glanzman, Kathie Bishop, Z. John Zhong, Sarah Gheuens, C. Frank Bennett, Eugene Schneider, Wildon Farwell, Darryl C. De Vivo. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2017; 377 (18): 1723 DOI: 10.1056/NEJMoa1702752


Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Most Popular On Medindia:

Recommended Reading

More News on:

Drug Toxicity Clinical Trials - Different Phases of the trial Amniocentesis Genetics and Stem Cells Signature Drug Toxicity Down Syndrome Progeria Cystic Fibrosis Drugs Banned in India Niemann-Pick Disease 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive